Showing 1791-1800 of 2038 results for "".
- American Academy of Optometry Launches Nationwide Search for New CEOhttps://modernod.com/news/american-academy-of-optometry-launches-nationwide-search-for-new-ceo/2480968/The American Academy of Optometry (AAO) has formed a search committee to identify candidates for the position of Chief Executive Officer. Current Chief Financial Officer (CFO)/Deputy CEO Richard Jones will serve as Interim Chief Executive Officer throughout the search. Mr. Jones has more than 20
- Study: AMD Strongly Associated With Heart Disease and Strokehttps://modernod.com/news/study-blinding-eye-disease-is-strongly-associated-with-heart-disease-and-stroke/2480958/Patients with a specific form of age-related macular degeneration (AMD) are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai. This study, published in the July issue of Retina, is the first t
- Global Data: Increasing Cataract Surgical Rates Will Drive Artificial Lenses Market to Reach $4.7 Billion by 2030https://modernod.com/news/global-data-increasing-cataract-surgical-rates-will-drive-artificial-lenses-market-to-reach-47-billion-by-2030/2480953/The global market for IOLs is forecast by GlobalData to steadily grow from $4.3 billion in 2021 to $4.7 billion by the end of the decade. The data and analytics company notes that this growth is primarily driven by the growing capacity of many hospitals and clinics across all regions to perform m
- Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimurahttps://modernod.com/news/iveric-bio-and-delsitech-enter-exclusive-agreement-for-development-of-sustained-release-zimura/2480948/Iveric bio and DelSiTech announced an exclusive global license agreement providing Iveric Bio with the right to develop and commercialize new formulations of Zimura (avacincaptad pegol) using DelSiTech’s silica-based sustained release technology. Under the terms of the l
- Measuring Levels of Proteins in Eye Fluid May Accurately Predict Need for Lifelong Macular Degeneration Therapyhttps://modernod.com/news/measuring-levels-of-proteins-in-eye-fluid-may-accurately-predict-need-for-lifelong-macular-degeneration-therapy/2480947/In a study of eye fluid from 38 patients, Johns Hopkins Medicine researchers say they have found that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration (AMD) may need lifelong, frequent eye injections to preserve v
- Oculis Announces First Patient Enrolled in Phase 3 OPTIMIZE Trial of OCS-01 in the Treatment of Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-first-patient-enrolled-in-phase-3-optimize-trial-of-ocs-01-in-the-treatment-of-inflammation-and-pain-following-cataract-surgery/2480939/Oculis SA announced that the first patient has been enrolled in its phase 3 OPTIMIZE trial evaluating the efficacy and safety of once-daily OCS-01 for the treatment of inflammation and pain following cataract surgery. OCS-01 is a novel, high concentration, preservative-free, topical formulat
- Kuria Therapeutics and Scohia Pharma Announce Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activatorhttps://modernod.com/news/kuria-therapeutics-and-scohia-pharma-announce-licensing-agreement-for-ophthalmic-and-dermal-rights-to-sco-116-a-novel-nrf2-activator/2480933/Kuria Therapeutics and Japanese biotech company Scohia Pharma announced that the companies have entered into a licensing agreement under which Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of SCO-116, one of Scohia's internally discov
- Opus Genetics Appoints Ben Yerxa, PhD, as Permanent Chief Executive Officerhttps://modernod.com/news/opus-genetics-appoints-ben-yerxa-phd-as-permanent-chief-executive-officer/2480923/Opus Genetics announced the appointment of Ben Yerxa, PhD, as Chief Executive Officer. Dr. Yerxa previously served as acting CEO of Opus, in addition to former roles as CEO of the Foundation Fighting Blindness and the Retinal Degeneration (RD) Fund, the venture arm of th
- Visionix and Right MFG to Enter a Long-Term Strategic Partnershiphttps://modernod.com/news/visionix-and-right-mfg-to-enter-a-long-term-strategic-partnership/2480863/Visionix, formerly Luneau Technology, and Japan-based Right MFG announced today that they have entered a long-term strategic partnership agreement with the aim of accelerating growth for both companies. Financial terms of the deal were not disclosed.
- Alcon Celebrates 75th Anniversaryhttps://modernod.com/news/alcon-celebrates-75-years-of-eye-care-innovation/2480862/Alcon marked the company’s 75th anniversary this week with its "Brilliant History. Brilliant Future." celebration. On May 16, 1947, Alcon Laboratories Inc. was incorporated and began manufacturing specialty pharmaceutical products in Fort Worth, Texas. To